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PURINE NUCLEOTIDES (such as ATP) and their metabolites (such as adenosine) are physiologically essential molecules in the heart. ATP is the universal currency of chemical energy in the cell, and more ATP is produced and consumed (per unit time) in cardiovascular tissue than anywhere else in the human body (26, 32) . Ischemia and hypoxia lead to an imbalance in ATP consumption/production, and the consequences can include arrhythmia, cellular damage, and ultimately cell death (18) . However, cardiomyocytes can resist the effects of ischemia and hypoxia if they are briefly exposed to a challenge either pharmacologically or hypoxically (14, 15, 20, 21, 27) . This effect, known as preconditioning (PC), has been extensively studied, and various factors, including adenosine and receptorcoupled signaling pathways, have been proposed to be involved (1, 19, 27) . Adenosine, a key element in PC, is not lipophilic and crosses cell membranes via nucleoside transporters (2, 12) . In cardiomyocytes, equilibrative nucleoside transporters (ENTs), which facilitate the movement of purine nucleosides down their endogenous concentration gradient, are responsible for the flux of adenosine across the plasma membrane (4 -6) . Extracellular adenosine interacts with adenosine receptors (A 1 , A 2A , A 2B , and/or A 3 ), and receptor activation results in the activation of signaling pathways that "resist" the stress caused by ischemia/hypoxia. ENTs are thus critical elements in modulating the local effects of adenosine. Moreover, the potentiation of adenosine receptor activation by drugs that inhibit ENTs, such as dipyridamole (DIPY), is a clinically relevant pharmacological intervention (9, 24, 34) .
We previously used the murine cardiomyocyte HL-1 cell line to investigate the role of ENTs in hypoxic or pharmacological PC and shown that PC involves adenosine, mouse (m)ENT1, and adenosine receptor activation (5, 6) . However, HL-1 cells also possess ENT2, which has been reported to transport purine nucleosides and to have a higher affinity for inosine, a major and metabolically stable adenosine metabolite (8, 31) . A growing body of data suggests that other purine nucleosides or nucleobases (e.g., inosine and adenine) have physiologically relevant actions in other tissues as a result of cell surface receptor signaling (7, 29, 30, 33) . Moreover, inosine has been implicated in cellular responses to ischemia in the brain and skeletal muscle and has been reported to activate A 3 receptors (7, 29, 30, 33) . Inosine is readily produced by the deamination of adenosine and/or by the deamination of AMP to IMP (by AMP deaminase) followed by dephosphorylation of IMP to inosine by 5Ј-nucleotidase. Intriguingly, recent data have suggested that IMP hydrolysis contributes significantly to adenosine and inosine pools (33) . Despite these observations, very little is known about the contribution of inosine to PC in the heart. Given our observation of high concentrations of inosine in HL-1 cells in response to hypoxia, we speculated that inosine might contribute to PC in cardiomyocytes and used the murine HL-1 cell line to identify the relative contributions of ENT1/ENT2 to adenosine /inosine release and to determine if inosine is involved in PC.
MATERIALS AND METHODS

Materials.
Claycomb medium and L-glutamine solution were purchased from JRH Biosciences (Lenexa, KS). FBS, antibiotic/antimycotic solution, norepinephrine, inosine, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), nitrobenzylthioinosine (NBTI), DIPY, and 8-(3-chlorostyryl)caffeine (CSC) were purchased from Sigma-Aldrich Canada (Oakville, ON, Canada). MRS-1220 and CGS-15943 were purchased from Tocris Cookson (Ellisville, MO). A Plexiglas GasPak container and Fyrite Oxygen Analyzer were purchased from VWR Canlab (Mississauga, ON, Canada).
Cell culture. HL-1 cells are a cardiac muscle cell line derived from the AT-1 mouse atrial cardiomyocyte tumor lineage. HL-1 cells were grown in Claycomb medium supplemented with 10% (vol/vol) FBS, 100 M norepinephrine, 4 mM L-glutamine, and 1ϫ antibiotic/antimycotic solution. Culture plates were precoated with 0.02% (wt/vol) gelatin solution. For viability assays and HPLC analysis, HL-1 cells were seeded on 60-mm dishes, and experiments were conducted when cells reached 75-80% cell confluency.
Hypoxic and pharmacological PC. The hypoxic PC protocol used for HL-1 cells consisted of 90-min hypoxia and 60-min normoxia for one cycle. Following this cycle, cells were exposed to 20 h of hypoxia. To determine whether inosine is involved in PC in HL-1 cells, cells were treated with 5 M inosine for 15 min prior to 20 h of hypoxia. Nonpreconditioned cells were exposed to 20 h of hypoxia. Control cells were exposed to normoxia for equivalent time.
For hypoxic challenge, HL-1 cells were transferred to a vented Plexiglas GasPak container and maintained at 37°C with a humidified hypoxic atmosphere of 2% O 2-5% CO2-93% N2. Control cells were maintained at 5% CO2-95% air at 37°C. For the hypoxic challenge, degassed medium was used. Oxygen concentrations in the chamber were measured using a FYRITE Oxygen Analyzer.
Adenosine receptors. To determine whether adenosine receptor activation was involved in pharmacological PC with inosine, HL-1 cells were treated with adenosine receptor agonists and antagonists that we have previously confirmed to be effective in this cell line (5) . Thus, HL-1 cells were treated with the general adenosine receptor antagonist CGS-15943 (4 nM), the specific A1 adenosine receptor antagonist DPCPX (1 M), the specific A2 adenosine receptor antagonist CSC (500 nM), and the specific A3 adenosine receptor antagonist MRS-1220 (200 nM) for 20 min before and during the treatment with 5 M inosine for 15 min followed by 20 h of hypoxia. We used pharmacological agents at concentrations that ensure maximal blockage of the respective receptors without interfering with ENT-dependant transport by pretesting them in adenosine transport assays (5) .
Cell viability. Following PC and/or hypoxia, cell viability was determined by a standard trypan blue exclusion assay. Eight fields of view were counted for each sample, and values shown as percentages of dead cells (means Ϯ SE).
HPLC analysis. Extracellular adenosine and inosine were measured as previously described for PC-12 cells (17) . HL-1 cells were plated on 60-mm dishes and grown to ϳ75-80% confluency. Cells were rinsed twice with 1.0 ml of Krebs solution (135 mM NaCl, 1.5 mM NaH2PO4, 5 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM glucose, and 15 mM HEPES). Prewarmed Krebs solution (1.25 ml) was added to each plate, and cells were incubated under normoxic conditions for 30 min. The solution was aspirated and replaced with degassed Krebs solution prior to 30 min of hypoxia. A control plate was incubated under normoxia for another 30 min. Cells were treated with NBTI (500 nM) in one plate and with NBTI (500 nM) ϩ DIPY (30 M) in another plate for 10 min before the medium was changed to Krebs' solution, during 30 min of normoxia in Krebs solution and during 30 min of hypoxia. Following hypoxic and normoxic treatment, the Krebs solution was collected and kept frozen at Ϫ80°C until analyzed for extracellular adenosine and inosine. To collect samples for measuring the intracellular levels of adenosine nucleotides and inosine, 0.7 ml of ice-cold 0.4 M perchloric acid was added to each plate, and cells were scraped and centrifuged for 10 min at 14,000 rpm at 4°C. Supernatants were collected and neutralized with 10 l of ice-cold 4 M K2CO3 per 100-l volume. Samples were kept on ice for 7-10 min and centrifuged again for 10 min at 14,000 rpm at 4°C. The final supernatants were immediately frozen at Ϫ80°C and kept frozen until analyzed for intracellular adenosine nucleotides and inosine. The pellets collected after the first centrifugation were dissolved in 300 l of 0.5 M NaOH for protein analysis.
Measurements of released adenosine and inosine and intracellular levels of adenosine nucleotides and inosine were performed by HPLC. A C18 column was used with UV detection at 259 nm. The mobile phase for extracellular adenosine and inosine contained 125 mM potassium dihydrogen phosphate, 1.5% (vol/vol) acetonitrile, 20 mM triethylamine, and 1.0 mM tetrabutylammonium hydrogen sulfate (pH 6.5) (10). The mobile phase for intracellular adenosine nucleotides and inosine contained 220 mM potassium phosphate (pH 6.9), 1% (vol/vol) methanol, and 0.3 mM tetrabutylammonium hydrogen sulfate. The pH of both mobile phases was adjusted with 8 M potassium hydroxide. The flow rate was 3 ml/min, and assays were performed at room temperature. Peaks were identified on the basis of retention times and comparison with standards.
Adenosine and inosine uptake. Uptake of [ 3 H]adenosine and [ 3 H] inosine (10 M) was measured at 5 s in the absence and presence of NBTI (100 nM) as previously described (4).
Data analysis. Statistical analysis was done using (one-way) ANOVA, followed by the Newman-Keuls test. All statistical analyses were done using GraphPad Prism 3.0a for Macintosh (GraphPad Software, San Diego, CA). A P value of Ͻ0.05 was considered to be statistically significant. Data are presented as means Ϯ SE.
RESULTS
We (5, 6) have previously shown that adenosine is released from HL-1 cardiomyocytes via ENT1 following hypoxic challenge, suggesting that ENT1 is a gatekeeper in PC. Therefore, inhibition of ENT1 by NBTI could effectively abolish PC unless ENT2 and inosine are involved. To determine whether inosine is an effective PC agent, we used our previous approach (5) , and, since both ENT1 and ENT2 exist in HL-1 cells (4), we investigated the relative contributions of ENT1 and ENT2 to PC.
Using our previously determined PC protocol, we found that inhibition of mENT1 alone using NBTI did not prevent PC (Fig. 1) . We speculated that purine nucleoside-dependent PC could still be occurring due to purine nucleoside flux via mENT2 or retention of intracellular pools of adenosine metab- olites leading to equivalent cell viability compared with PC. To determine if there were changes in purinergic nucleotides and their metabolites following hypoxic challenge, we compared extracellular concentrations of adenosine and inosine following hypoxic challenge and in the presence of the ENT1 inhibitor NBTI (Fig. 2) . These data showed that levels of inosine in the extracellular medium of cells exposed to hypoxic challenge were significantly higher (ϳ20-fold) than those of adenosine. Moreover, inhibition of mENT1 (by NBTI) did not significantly affect extracellular concentrations of inosine (suggesting efflux via mENT2), whereas inhibition of both mENT1 and mENT2 (using NBTI ϩ DIPY) significantly reduced extracellular inosine concentration, although not to basal levels (suggesting some extracellular production). These data suggest that mENT2 could be responsible for the release of inosine, which could in turn contribute to PC.
Since it is clear that hypoxic challenge leads to significant extracellular levels of inosine, we then asked if inosine could act as a pharmacological PC agent, analogous to adenosine. Therefore, we tested whether inosine could precondition HL-1 cells under identical conditions to those previously described (Fig. 3) . Based on our observation that extracellular concentrations of inosine reached 7 M after 30 min of hypoxia, we used 5 M inosine to pharmacologically precondition the cells in these experiments. We found that inosine is an effective PC agent and that it appears to act via A 1 receptors, similarly to adenosine, but has no or very little effect through A 3 receptors, in contrast to adenosine, which we have previously found to act through both receptors (5) . Finally, to ensure that inosine was not triggering protection by elevating extracellular adenosine (and thus A 1 adenosine receptor agonism) through competition for uptake, we measured 2-chloradenosine uptake in the presence and absence of 5 M inosine and found no inhibitory effect (data not shown).
It is evident that there are substantial levels of extracellular inosine following hypoxic challenge, and we hypothesized that some of this inosine is being released by ENT2; thus, we needed to confirm that the inosine was being produced intracellularly and released rather than adenosine being released and rapidly deaminated to inosine extracellularly. Therefore, we measured intracellular levels of inosine following hypoxic challenge in the presence of ENT1 and ENT2 inhibitors (Fig. 4 ) and compared these with previously described extracellular levels. We found that there was a significant increase in intracellular inosine following hypoxia and that it was primarily released via ENT2 with a smaller component released via ENT1.
While our data are suggestive of flux of inosine via ENT2, transport of this purine by ENT2 has not been demonstrated in HL-1 cells. Therefore, we confirmed that ENT2 could transport inosine under typical conditions used for transport characterizations (4). Our data (Fig. 5) showed that exogenously added inosine was transported by both ENT1 and ENT2 at approximately equal levels, whereas adenosine was primarily transported by ENT1.
Finally, we were interested in the source of inosine being released from cells. In a previous study (5) aimed at measuring adenosine levels following hypoxic challenge, we included erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) in the extracellular medium to ensure that we could detect differences in the release of adenosine under varying conditions before it was metabolized extracellularly. However, adenosine has a short half-life and is metabolized rapidly in vivo. Therefore, in these experiments, we did not include EHNA and compared extracellular adenosine and inosine under identical conditions. Changes in the concentrations of intracellular adenosine metabolites following hypoxic challenge in the presence and absence of nucleoside transport inhibitors are shown in Fig. 6 . We found that there was a striking increase in the AMP concentration following hypoxic challenge. Further metabolism of AMP resulted in high levels of adenosine, although intracellular levels of adenosine were very low, presumably because it was metabolized rapidly in the absence of EHNA. In contrast, we noted that intracellular inosine levels increased markedly following hypoxic challenge, possibly as a consequence of adenosine metabolism. Moreover, intracellular concentrations of inosine were even higher in the presence of inhibitors, suggesting that under hypoxic conditions, inosine can be produced intracellularly and released, down its endogenous concentration gradient, via ENTs.
In conclusion, we propose that inosine is an effective and physiologically relevant PC agent that can be produced intracellularly and released by cardiomyocytes via ENTs following hypoxic challenge and that contributes to PC via A 1 adenosine receptors (Fig. 7) .
DISCUSSION
Adenosine is well established to play a role in PC in a number of physiological settings, including the cardiovascular system (19) . However, there is now evidence that adenosine metabolites may play also role in cardiovascular physiology. More than 20 years ago, the purine nucleoside inosine was reported to be a protective agent in myocardial ischemia (11) . More recently, there have been reports that inosine reduces ischemic injury in the brain (13, 28) and that it has immunomodulatory functions (13) . Inosine is a hydrophilic purine nucleoside and is transported across cell membranes by members of the ENT family, with ENT2 appearing to be its preferred route (8) . Interestingly, ENT2 is highly expressed in muscle (8, 23) , suggesting a possible physiological role for inosine and ENT2 in the cardiovasculature. Thus, the presence of ENT2, along with ENT1, in cardiomyocytes raised the possibility of differing or overlapping physiological roles for these proteins. Moreover, the reported differential transport preferences of ENT1 and ENT2 for adenosine and inosine, in addition to the ability of ENT2 to transport nucleobases, raised the possibility that purine nucleosides other than adenosine were relevant in cardiovascular physiology. Since adenosine and ENT1 have already been implicated in hypoxic PC in HL-1 cells (5, 6), we were interested in determining if there was also a contribution by ENT2 and inosine to this process. Our data demonstrate that ENT2 and inosine contribute to PC in HL-1 cells, supporting the notion that inosine is a physiologically relevant neuro-and cardioprotective molecule (11, 13, 28) . In our study, the majority of inosine produced in response to hypoxic challenge, and responsible for PC, appears to be intracellular (probably from the metabolism of adenosine via adenosine deaminase, which is found both intra-and extracellularly in cardiomyocytes). However, we also noted the presence of some extracellular inosine even with complete ENT inhibition, supporting previous observations of high levels (and a possible extracellular source) of inosine.
These data correlate with a recent study (33) using adenosine deaminase knockout mice in which inosine levels were not as low in the cardiovasculature as would be expected if all inosine were being produced by the deamination of adenosine. Thus, IMP may be a significant, and underappreciated, source of inosine in cardiomyocytes (33) .
While inosine has been reported to interact with A 3 receptors, for which it has been reported to have a high affinity in mast cells (16), we found no evidence of an interaction with A 3 receptors. Rather, we noted that the PC effects of inosine are A 1 adenosine receptor dependent, which correlates with previous findings demonstrating that loss of the A 1 adenosine receptor compromises ischemic tolerance (25, 33) . These observations suggest that cell type-specific differences in adenosine physiology, relating to receptor specificity and coupling, may exist (22) .
Taken together, our data suggest that inosine (and possibly other adenosine metabolites) needs to be more thoroughly investigated in a myocardial setting to ensure that the complexity of factors involved in PC and cardiomyocyte physiology are fully understood. The ratio of local extracellular concentrations of inosine to adenosine may play a role in determining the cellular response given the differing, but perhaps overlapping, affinities for adenosine receptors and transporters (13) . While adenosine is generally considered to be a beneficial purine nucleoside, excess extracellular adenosine can also be detrimental to a number of cell types, leading to apoptosis and inflammation (3) . Thus, cellular control of the flux and receptor-dependent signaling of purine nucleosides is likely to be important for appropriate cellular responses in metabolically active cells and tissues such as those in the cardiovasculature. Taken together, our observations suggest that cardiomyocyte responses to hypoxic PC may involve a more complex set of players than previously thought, and future studies should take into account the contribution of inosine and differing roles of the various ENT isoforms.
